12:00 AM
May 27, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Lurbinectedin: Phase Ib started

PharmaMar began an open-label, dose-escalation, European Phase Ib trial to evaluate PM01183 in combination with capecitabine in about 30-40 patients with unresectable metastatic breast, metastatic colon or pancreatic cancer. PM01183 is in...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >